spacer
home > directory > CMAB Biopharma
PHARMACEUTICAL INDUSTRY DIRECTORY

CMAB Biopharma

CMAB Biopharma
CMAB Biopharma is a full service, pure play Contract Development and Manufacturing Organisation (CDMO), which provides bespoke solutions for mammalian cell culture derived antibodies and recombinant proteins.

Our mission is to be the biologic CDMO of choice for biopharma companies from around the world by leveraging our state-of-the-art manufacturing facility, our large-scale production capacity and our ability to meet international quality requirements.

Established in 2017 with strong financial backing from our three main shareholders (C-Bridge Capital, CD Capital and BioBay), our 10,500 m2 (112,980 ft2) facility is located just outside of Shanghai in Suzhou, China. We have grown rapidly in 18 months to 165 full time employees with international offices founded in Switzerland, Toronto and Singapore. Our senior management is composed of experts with experience working in large international biotechnology organisations such as Genentech, Eli Lilly, Pfizer, Amgen and Janssen as well as CDMOs such as Lonza, Wuxi, Therapure and MabPlex.

At CMAB biopharma, we provide expertise and experience in process and analytical development, drug substance (DS) and drug product (DP) cGMP manufacturing. Our process development and analytical development labs are fully equipped with the latest equipment including a mass spectrometer, which is used for protein characterisation. Our four parallel upstream suites offer flexible cGMP production scales using multiple single use bioreactors (SUBs) ranging from 200 to 2,000 L volumes. CMAB is currently installing a fully automated aseptic fill / finish line along with a lyophiliser, which will be capable of producing commercial quantities of DP in early 2020. Finally, we can also provide our clients with lot release testing and stability studies.

Our operational protocols and quality standards comply with FDA, EMA and NMPA guidelines, which enables CMAB Biopharma to produce cGMP material for global clients. In addition, our quality standards align to the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S), International Committee on Harmonization (ICH) and World Health Organisation (WHO) guidelines.

To learn more about CMAB Biopharma or to get in contact with us directly, please visit www.cmabbio.com or write to us at hello@cmabbio.com. We look forward to hearing from you.
phone +41 61 564 03 57
email hello@cmabbio.com
web www.cmabbio.com
email Teichgässlein 9, 4058 Basel, Switzerland
 
spacer

Member login

E-mail address:

Password:
Remember me

Industry Events

FlyPharma Europe

22-23 October 2019, Copenhagen, Denmark

The FlyPharma Conference Europe 2019 is aimed at forward-thinking individuals and businesses that are ready to uncover the potential in their pharma supply chain. The event offers an interactive platform to discuss current and future challenges within pharma and cargo, with topics including market trends, cold chain innovations, latest regulatory demands, security technology, and how to encourage collaboration between supply chain players. There will be plenty of networking opportunities, including a complimentary evening networking event, where delegates can meet and catch up with senior and executive pharma and cargo professionals – gaining strong, new industry contacts and building on existing ones.
More info >>

 
News and Press Releases

Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research

Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health (signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signant makes it easier to participate in – and sites and study teams to run – clinical trials. This intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable sponsors and CROs to extend the reach of drug development, expand patient opportunities and improve data quality.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement